Category Archive for: ‘AHS’

New Experimental Drug Telcagepant Significantly Improves Migraine With Fewer Side Effects

Merck‚Äôs Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase III Study Oral CGRP Receptor Antagonist Provided Similar Migraine Relief with Fewer Adverse Events Compared to Zolmitriptan BOSTON–(BUSINESS WIRE)–Merck & Co., Inc. today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine …

Read More